TY - JOUR
T1 - Effectiveness of the BNT162b2 mRNA COVID-19 vaccine in pregnancy
AU - Dagan, Noa
AU - Barda, Noam
AU - Biron-Shental, Tal
AU - Makov-Assif, Maya
AU - Key, Calanit
AU - Kohane, Isaac S.
AU - Hernán, Miguel A.
AU - Lipsitch, Marc
AU - Hernandez-Diaz, Sonia
AU - Reis, Ben Y.
AU - Balicer, Ran D.
N1 - Funding Information: N.D., N.B., M.M.A. and R.D.B. report institutional grants to the Clalit Research Institute from Pfizer outside the submitted work and unrelated to COVID-19, with no direct or indirect personal benefits. M.L. reports grants from Pfizer, personal fees from Merck, Bristol Meyers Squibb, Sanofi Pasteur and Janssen, grants from the National Institutes of Health (NIH), the National Institute for Health Research, Centers for Disease Control and Prevention, Open Philanthropy Project, Wellcome Trust and Pfizer outside the submitted work; he has provided unpaid advice on COVID vaccines or vaccine studies to 1Day Sooner (nonprofit), Pfizer, AstraZeneca, Janssen and COVAXX (United Biosciences). M.A.H. reports grants from the NIH and Veterans Affairs, and personal fees from Cytel and ProPublica. S.H.D. reports consulting fees from Roche and UCB outside the submitted work. B.Y.R. reports grants from the NIH outside the submitted work. The other authors declare no competing interests. Funding Information: This study was supported by the Ivan and Francesca Berkowitz Family Living Laboratory Collaboration at Harvard Medical School and Clalit Research Institute. M.L. was supported by the Morris-Singer Foundation. Publisher Copyright: © 2021, The Author(s), under exclusive licence to Springer Nature America, Inc.
PY - 2021/10/1
Y1 - 2021/10/1
N2 - To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms and 89% (43–100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.
AB - To evaluate the effectiveness of the BNT162b2 messenger RNA vaccine in pregnant women, we conducted an observational cohort study of pregnant women aged 16 years or older, with no history of SARS-CoV-2, who were vaccinated between 20 December 2020 and 3 June 2021. A total of 10,861 vaccinated pregnant women were matched to 10,861 unvaccinated pregnant controls using demographic and clinical characteristics. Study outcomes included documented infection with SARS-CoV-2, symptomatic COVID-19, COVID-19-related hospitalization, severe illness and death. Estimated vaccine effectiveness from 7 through to 56 d after the second dose was 96% (95% confidence interval 89–100%) for any documented infection, 97% (91–100%) for infections with documented symptoms and 89% (43–100%) for COVID-19-related hospitalization. Only one event of severe illness was observed in the unvaccinated group and no deaths were observed in either group. In summary, the BNT162b2 mRNA vaccine was estimated to have high vaccine effectiveness in pregnant women, which is similar to the effectiveness estimated in the general population.
UR - http://www.scopus.com/inward/record.url?scp=85114643001&partnerID=8YFLogxK
U2 - https://doi.org/10.1038/s41591-021-01490-8
DO - https://doi.org/10.1038/s41591-021-01490-8
M3 - Article
C2 - 34493859
SN - 1078-8956
VL - 27
SP - 1693
EP - 1695
JO - Nature Medicine
JF - Nature Medicine
IS - 10
ER -
